Smith Anglin Financial’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $644K | Buy |
3,468
+36
| +1% | +$6.68K | 0.06% | 106 |
|
|
2025
Q1 | $719K | Sell |
3,432
-544
| -14% | -$114K | 0.08% | 97 |
|
|
2024
Q4 | $707K | Buy |
3,976
+199
| +5% | +$35.4K | 0.07% | 96 |
|
|
2024
Q3 | $746K | Buy |
3,777
+237
| +7% | +$46.8K | 0.07% | 89 |
|
|
2024
Q2 | $607K | Buy |
3,540
+6
| +0.2% | +$1.03K | 0.06% | 94 |
|
|
2024
Q1 | $643K | Buy |
3,534
+253
| +8% | +$46.1K | 0.07% | 95 |
|
|
2023
Q4 | $508K | Buy |
3,281
+56
| +2% | +$8.68K | 0.06% | 102 |
|
|
2023
Q3 | $481K | Buy |
3,225
+29
| +0.9% | +$4.32K | 0.06% | 96 |
|
|
2023
Q2 | $431K | Buy |
3,196
+35
| +1% | +$4.72K | 0.05% | 105 |
|
|
2023
Q1 | $504K | Buy |
3,161
+118
| +4% | +$18.8K | 0.08% | 93 |
|
|
2022
Q4 | $492K | Sell |
3,043
-73
| -2% | -$11.8K | 0.09% | 81 |
|
|
2022
Q3 | $418K | Buy |
3,116
+30
| +1% | +$4.02K | 0.09% | 85 |
|
|
2022
Q2 | $473K | Sell |
3,086
-212
| -6% | -$32.5K | 0.14% | 75 |
|
|
2022
Q1 | $535K | Sell |
3,298
-6
| -0.2% | -$973 | 0.12% | 71 |
|
|
2021
Q4 | $447K | Buy |
3,304
+218
| +7% | +$29.5K | 0.08% | 90 |
|
|
2021
Q3 | $333K | Sell |
3,086
-253
| -8% | -$27.3K | 0.06% | 105 |
|
|
2021
Q2 | $376K | Buy |
3,339
+43
| +1% | +$4.84K | 0.07% | 97 |
|
|
2021
Q1 | $357K | Sell |
3,296
-44
| -1% | -$4.77K | 0.08% | 96 |
|
|
2020
Q4 | $358K | Buy |
+3,340
| New | +$358K | 0.06% | 88 |
|